The global demand for Biologics and Biosimilars Market is presumed to reach the market size of nearly USD 109.8 Billion by 2032 from USD 29.62 Billion in 2023 with a CAGR of 15.67% under the study period 2024-2032.
Biologics are therapeutic agents sourced from living organisms, such as proteins, nucleic acids, and cells, used to treat various medical conditions, including autoimmune disorders, cancer, and chronic diseases. Biologics and biosimilars are characterized by their complexity and production through biotechnological methods. They are medical products highly similar to an already approved reference biologic, with no clinically meaningful differences in safety or efficacy. Biologics and biosimilars offer a cost-effective alternative to original biologics, contributing to increased accessibility and affordability of biologic therapies.
The biologics and biosimilars market is driven by the rising prevalence of chronic & autoimmune diseases that require advanced therapeutic options. Biologics' high efficacy and specificity in treating complex conditions propel their demand. Additionally, the patent expiration of several blockbuster biologics has opened opportunities for developing and commercializing biosimilars, which offer cost-effective alternatives and can enhance patient access to life-saving treatments. Technological advancements in biotechnology and the growing focus on personalized medicine further fuel biologics and biosimilars market growth. Opportunities are also in emerging markets, where rising healthcare access and infrastructure improvements drive biologics and biosimilar adoption. Ongoing research into novel biologic therapies and biosimilar products continues to expand the market potential. However, stringent regulatory requirements and high development costs may restrain market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Biologics and Biosimilars. The growth and trends of Biologics and Biosimilars industry provide a holistic approach to this study.
This section of the Biologics and Biosimilars market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
By Application
This section covers the regional outlook, which accentuates current and future demand for the Biologics and Biosimilars market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Biologics and Biosimilars market include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Roche, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1. PREFACE
1.1. Report Description
1.1.1 Objective
1.1.2 Target Audience
1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1 Market Research Process
1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3. BIOLOGICS AND BIOSIMILARS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Type
3.7.2 Market Attractiveness Analysis By Application
3.7.3 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS BY TYPE
5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Monoclonal Antibodies Historic and Forecast Sales By Regions
5.4. Interferon Historic and Forecast Sales By Regions
5.5. Erythropoietin Historic and Forecast Sales By Regions
5.6. Insulin Historic and Forecast Sales By Regions
5.7. Vaccines Historic and Forecast Sales By Regions
6. GLOBAL BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS BY APPLICATION
6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Tumor Historic and Forecast Sales By Regions
6.4. Diabetes Historic and Forecast Sales By Regions
6.5. Cardiovascular Historic and Forecast Sales By Regions
6.6. Hemophili...
